Metabolic dysfunction-associated steatotic liver disease: An opportunity for collaboration between cardiology and hepatology.
Atherosclerosis
; 392: 117523, 2024 May.
Article
em En
| MEDLINE
| ID: mdl-38522165
ABSTRACT
Altered metabolic function has many detrimental effects on the body that can manifest as cardiovascular and liver diseases. Traditional approaches to understanding and treating metabolic dysfunction-associated disorders have been organ-centered, leading to silo-type disease care. However, given the broad impact that systemic metabolic dysfunction has on the human body, approaches that simultaneously involve multiple medical specialists need to be developed and encouraged to optimize patient outcomes. In this review, we highlight how several of the treatments developed for cardiac care may have a beneficial effect on the liver and vice versa, suggesting that there is a need to target the disease process, rather than specifically target the cardiovascular or liver specific sequelae of metabolic dysfunction.
Palavras-chave
Texto completo:
1
Bases de dados:
MEDLINE
Assunto principal:
Cardiologia
/
Gastroenterologia
Limite:
Humans
Idioma:
En
Revista:
Atherosclerosis
Ano de publicação:
2024
Tipo de documento:
Article